Phase II trial of S-1 therapy for advanced or recurrent esophageal cancer resistant or intolerable existing treatments - Phase II trial of S-1 therapy for advanced or recurrent esophageal cancer resistant or intolerable existing treatments

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine0 个研究点目标入组 50 人开始时间: 2016年8月26日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Previous treatment with S-1 2) With active diseases (interstitial pneumonia, fibroid lung, intestinal obstruction, uncontrollable diabetes millutus or hypertentsion, history of myocardial infarction within 6 months, or unstable angina pectoris, liver cirrhosis, renal failure) 3) Simultaneous or metachronous cancers, with the exception of tumor curable with therapy before diagnosis of esophageal cancer 4) History of severe allergic reactions to pyrimidine fluoride drug 5) Active infection 6) With severe diarrhea 7) With symptomatic metastasis to nerve 8) Psychosis 9) Patients requiring the administration of flucytosine, phenytoin or warfarin potassium 10) Pregnant or lactating women, women of childbearing potential or women who like to have children in future 11) Participant to other clinical trials 12) Any patients judged by the investigator to be unfit to participate in the study

发起方

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine